Cargando…

Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model

BACKGROUND: Graft-vs-host disease (GVHD) is a major complication of allogenic bone marrow transplantation (BMT). Targeting costimulatory molecules with antagonist antibodies could dampen the excessive immune response that occurs, while preserving the beneficial graft vs leukemia (GVL) of the allogen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burlion, Aude, Brunel, Simon, Petit, Nicolas Y., Olive, Daniel, Marodon, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491549/ https://www.ncbi.nlm.nih.gov/pubmed/28713380 http://dx.doi.org/10.3389/fimmu.2017.00756

Ejemplares similares

Human multipotent adult progenitor cells effectively reduce graft‐vs‐host disease while preserving graft‐vs‐leukemia activity
por: Metheny, Leland, et al.
Publicado: (2021)

Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions
por: Krieger, Elizabeth, et al.
Publicado: (2020)

Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease
por: Bailey, Christopher, et al.
Publicado: (2023)

A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system
por: Burlion, Aude, et al.
Publicado: (2019)

Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice
por: Aubert, Nicolas, et al.
Publicado: (2021)

GRAFT-VS.-HOST REACTION IN TISSUE CULTURE
por: Auerbach, Robert, et al.
Publicado: (1973)

Macrophage regulation of graft-vs-host disease
por: Hong, Ya-Qun, et al.
Publicado: (2020)

Therapeutic effects of STAT3 inhibition by nifuroxazide on murine acute graft graft-vs.-host disease: Old drug, new use
por: Jia, Huijie, et al.
Publicado: (2017)

Graft-vs.-host-associated immune suppression is activated by recognition of allogeneic murine I-A antigens
Publicado: (1983)

Serum-mediated inhibition of graft-vs.-host reaction
Publicado: (1975)

A novel monoclonal antibody against human B7-1 protects against chronic graft-vs.-host disease in a murine lupus nephritis model
por: Shen, Lijun, et al.
Publicado: (2020)

T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity
por: Lum, Su Han, et al.
Publicado: (2022)

GRAFT-VS.-HOST REACTIONS IN RECIPROCAL HYBRID MICE : I. DISSOCIATION OF T-CELL ACTIVITIES IN THE MIXED LYMPHOCYTE REACTION AND TWO GRAFT-VS.-HOST ASSAYS
por: Morse, Herbert C., et al.
Publicado: (1974)

Inhibition of the JAK/STAT Signaling Pathway in Regulatory T Cells Reveals a Very Dynamic Regulation of Foxp3 Expression
por: Goldstein, Jérémie D., et al.
Publicado: (2016)

Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease
por: Villa, Nancy Y., et al.
Publicado: (2018)

Graft-vs-Host Disease Colitis After Lung Transplant
por: Kanthasamy, Kavin, et al.
Publicado: (2019)

Follicular Graft Vs Host Reaction: A Rare Presentation
por: Vashisht, Deepak, et al.
Publicado: (2020)

Biomarkers of graft-vs-host disease: Understanding and applications for the future
por: Nagasawa, Masayuki
Publicado: (2021)

A delicate balance: CD73-generated adenosine limits the severity of graft vs. host disease but also constrains the allogeneic graft vs. tumor effect
por: Thompson, Linda F., et al.
Publicado: (2013)

Grafts for Ridge Preservation
por: Jamjoom, Amal, et al.
Publicado: (2015)

Improved survival outcomes and restoration of graft‐vs‐leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia
por: Cho, Byung‐Sik, et al.
Publicado: (2019)

Cytokine Detection and Modulation in Acute Graft vs. Host Disease in Mice
por: Knulst, A. C., et al.
Publicado: (1994)

Association of lpr gene with graft-vs.-host disease-like syndrome
Publicado: (1985)

Tumor-targeting vaccination instructs graft-vs.-tumor immune responses
por: Manzo, Teresa, et al.
Publicado: (2013)

Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease
por: Thangavelu, Govindarajan, et al.
Publicado: (2019)

Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance
por: Yu, Hongshuang, et al.
Publicado: (2019)

Inflammatory Cytokine Networks in Gastrointestinal Tract Graft vs. Host Disease
por: Piper, Clint, et al.
Publicado: (2019)

The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease
por: Bastian, David, et al.
Publicado: (2019)

Relevance of proteolysis and proteasome activation in fatty liver graft preservation: An Institut Georges Lopez-1 vs University of Wisconsin appraisal
por: Zaouali, Mohamed Amine, et al.
Publicado: (2017)

IL-17C Mitigates Murine Acute Graft-vs.-Host Disease by Promoting Intestinal Barrier Functions and Treg Differentiation
por: Gong, Huanle, et al.
Publicado: (2018)

IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects
por: Liu, Yuejun, et al.
Publicado: (2014)

Repair of large segmental bone defects: BMP-2 gene activated muscle grafts vs. autologous bone grafting
por: Betz, Oliver B, et al.
Publicado: (2013)

Graft Rejection Rate and Graft Failure Rate of Penetrating Keratoplasty (PKP) vs Lamellar Procedures: A Systematic Review
por: Akanda, Zarique Z., et al.
Publicado: (2015)

Combination of IL-2, rapamycin, DNA methyltransferase and histone deacetylase inhibitors for the expansion of human regulatory T cells
por: Miyara, Makoto, et al.
Publicado: (2016)

Tumor necrosis factor receptor family costimulation increases regulatory T‐cell activation and function via NF‐κB
por: Lubrano di Ricco, Martina, et al.
Publicado: (2020)

MECHANISM OF GRAFT-VERSUS-HOST-INDUCED LYMPHADENOPATHY IN MICE : TRAPPING VS. PROLIFERATION
por: Emeson, Eugene E., et al.
Publicado: (1973)

Connective tissue graft vs. emdogain: A new approach to compare the outcomes
por: Sayar, Ferena, et al.
Publicado: (2013)

Chronic graft-vs-host disease in 2016: a major challenge and an opportunity
por: Pulanić, Dražen, et al.
Publicado: (2016)

Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease
por: Sánchez-Ortega, Isabel, et al.
Publicado: (2016)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tue3g8uhl1jminfu4jlpkvoh8i